← All trials
NCT01591200
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2012
- Primary completion
- Apr 1, 2016
- Completion date
- Apr 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Stempeutics Research Pvt LtdLead sponsor
- Melaka Manipal Medical CollegeOverall official - principal investigator
- Breach Candy Hospital, MumbaiOverall official - principal investigator
- Centre for Liver Research & Diagnostics, HyderabadOverall official - principal investigator
- Mediciti HospitalOverall official - principal investigator
- Sahyadri Speciality HospitalOverall official - principal investigator
- Rajasthan University of Health SciencesOverall official - principal investigator
- Ruby Hall Clinic, PuneOverall official - principal investigator
- Sanjay Gandhi Postgraduate Institute of Medical SciencesOverall official - principal investigator
- Bombay Hospital & Medical Research CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.